Home > Insider Trading > Filing (0001447362-22-000052)

Filing Details

Accession Number:: 0001447362-22-000052
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-03-31 18:08:15
Reporting Period:: 2022-03-29

Accepted Time:: 2022-03-31 18:08:15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1447362	Castle Biosciences Inc	CSTL	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1236397	Daniel Bradbury	C/O Castle Biosciences, Inc. 505 S. Friendswood Drive, Suite 401 Friendswood TX 77546		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-03-29	3,852	$44.81	189,104	No	4	S	Indirect	By LLC
Common Stock	Disposition	2022-03-29	2,500	$45.46	100,037	No	4	S	Indirect	By Daniel Bradbury Irrecovable Descendant's Trust
Common Stock	Disposition	2022-03-29	2,500	$45.95	100,062	No	4	S	Indirect	By Annette Bradbury Irrecovable Descendant's Trust
Common Stock	Disposition	2022-03-30	3,852	$44.04	185,252	No	4	S	Indirect	By LLC
Common Stock	Disposition	2022-03-30	1,988	$45.17	98,049	No	4	S	Indirect	By Daniel Bradbury Irrecovable Descendant's Trust
Common Stock	Disposition	2022-03-30	512	$45.60	97,537	No	4	S	Indirect	By Daniel Bradbury Irrecovable Descendant's Trust
Common Stock	Disposition	2022-03-30	2,500	$45.96	97,562	No	4	S	Indirect	By Annette Bradbury Irrecovable Descendant's Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By LLC
No	4	S	Indirect	By Daniel Bradbury Irrecovable Descendant's Trust
No	4	S	Indirect	By Annette Bradbury Irrecovable Descendant's Trust
No	4	S	Indirect	By LLC
No	4	S	Indirect	By Daniel Bradbury Irrecovable Descendant's Trust
No	4	S	Indirect	By Daniel Bradbury Irrecovable Descendant's Trust
No	4	S	Indirect	By Annette Bradbury Irrecovable Descendant's Trust

Footnotes

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on November 30, 2021.
This transaction was executed in multiple trades at prices ranging from $44.340 to $45.140, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares.
This transaction was executed in multiple trades at prices ranging from $45.140 to $45.880, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries.
This transaction was executed in multiple trades at prices ranging from $45.880 to $46.140, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries.
This transaction was executed in multiple trades at prices ranging from $43.630 to $44.520, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $44.520 to $45.510, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $45.520 to $45.690, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $45.690 to $46.415, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.